Quarterly report pursuant to Section 13 or 15(d)

Intangible Asset (Details Narrative)

v3.8.0.1
Intangible Asset (Details Narrative) - USD ($)
 3 Months Ended
Mar. 19, 2018
Mar. 31, 2018
Mar. 31, 2017
Capitalized cost   $ 3,037,147  
Business combination of tax basis   $ 1,782  
Number of shares acquired in exchange for common stock   2,090,301
Amortization expense   $ 25,435
Weighted average amortization period for intangible asset   14 years  
Future amortization expense, twelve months   $ 788,495  
Future amortization expense, year two   788,495  
Future amortization expense, year three   788,495  
Future amortization expense, year four   788,495  
Future amortization expense, year five   788,495  
CoNCERT Pharmaceuticals, Inc [Member]      
Capitalized cost   11,038,929  
Transaction costs   $ 1,782  
Option exercised in exchange for common stock $ 8,000,000    
Number of shares acquired in exchange for common stock 2,090,301    
Percentage of common stock holdings 6.58%    
Precentage of issued and outstanding common stock diluted basis 5.93%    
Percentage of royalty 15.00%    
Proceeds from royalty receivable $ 8,000,000    
Proceeds from common stock 8,000,000    
CoNCERT Pharmaceuticals, Inc [Member] | Additional Paid-In Capital [Member]      
Proceeds from royalty receivable $ 8,000,000